Theradex (Europe)
Theradex (Europe) is recorded as a service provider in 8 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 8 of 8 trials · Latest update first
A Modular Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation, and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 as monotherapy and in combination in Patients with Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer
Sponsor Ellipses Pharma Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer
Sponsor Iovance Biotherapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Modular, Open-label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of EP0031 in Patients with Advanced RET-altered Malignancies
Sponsor Ellipses Pharma Limited
- Start (EU)
- Latest update
- Estimated end
An Open-Label, Multicentre Phase 1b/2a Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to FcγRIIB (CD32b), in Combination with Ipilimumab and Pembrolizumab in Participants with Unresectable or Metastatic Melanoma
Sponsor BioInvent International AB
- Start (EU)
- Latest update
- Estimated end
Phase II, multi‑cohort trial of neoadjuvant and post‑surgery IO102‑IO103 and pembrolizumab in patients with selected resectable tumors
Sponsor IO Biotech ApS
- Start (EU)
- Latest update
- Estimated end
A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with Pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of Head and Neck (SCCHN), or Metastatic Urothelial Bladder Cancer (mUBC)
Sponsor Io Biotech ApS
- Start (EU)
- Latest update
- Estimated end
An open-label phase 1b/2 study assessing the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma
Sponsor Alligator Bioscience AB
- Start (EU)
- Latest update
- Estimated end
- Not reported
EORTC 1333-GU: A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone (PEACE III)
Sponsor European Organisation For Research And Treatment Of Cancer
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Theradex (Europe)?
The 2026-10-09 snapshot links Theradex (Europe) to 8 distinct CTIS trials. Recorded services include Data management, Medical writing, Regulatory services, Clinical monitoring, among 12 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Theradex (Europe)?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Respiratory. Recorded phases include Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Theradex (Europe) conducted?
The linked trials record locations in 10 countries, including Spain, France, Germany, Belgium, Italy. These are trial locations, not confirmed office locations or countries where Theradex (Europe) delivered services.
What can this page tell me about Theradex (Europe)'s trial experience?
Browse 8 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Theradex (Europe). Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Theradex (Europe) Limited